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N-(4-hydroxyphenyl)retinamide (HPR) is a synthetic retinoic acid
analogue under investigation in clinical trials as preventive and
therapeutic agent. In animal models HPR has shown chemopre-
ventive efficacy against mammary gland, urinary bladder, seminal
vesicle and prostate carcinogenesis and therapeutic efficacy
against mammary, prostate and ovarian tumours (Formelli et al,
1996). In vitro studies have demonstrated that HPR has significant
antiproliferative activity associated with induction of apoptosis in
several tumour cell types including breast, prostate, leukaemia,
head and neck, neuroblastoma and ovary (Formelli et al, 1996).
The mechanism of action of HPR has not yet been clarified. Some
studies suggest that the effects of this retinoid are mediated
through signalling of retinoic acid receptors (RARs) and retinoid
X receptors (RXRs) (Fanjul et al, 1996; Supino et al, 1996;
Pergolizzi et al, 1999). Other results suggest that HPR can act as a
pro-oxidant and induce apoptosis by eliciting oxidative stress
(Oridate et al, 1997). In humans, HPR has already shown efficacy
in oral leukoplakia and lichen planus (Formelli et al, 1996).
Recently, reductions in the incidence of contralateral breast cancer
and ipsilateral breast cancer reappearance have been reported in
premenopausal women with early breast cancer treated with HPR
(Veronesi et al, 1999). Promising preliminary results suggest that
HPR can protect against ovarian cancer (De Palo et al, 1995;
Veronesi et al, 1999) and clinical trials are in progress to test the
effects of the retinoid against the tumour. 
A characteristic of retinoid treatment is that discontinuation of
treatment leads to recurrence of the lesion. However, as occurs
with chemotherapeutic drugs, continuous retinoid treatment might
cause development of drug resistance. Since no data are available
on resistance to HPR, we investigated whether this event occurs
with the retinoid and attempted to evaluate the molecular basis of
the effect. HPR-resistant cells (A2780/HPR), were developed by
continuous in vitro exposure to HPR of A2780 human ovarian
carcinoma cells, which have been shown to be very sensitive to the
growth-inhibitory effect of HPR (Supino et al, 1996). To under-
stand the possible basis of the decreased HPR sensitivity, we
investigated whether the generation of reactive oxygen species and
HPR uptake/metabolism are altered in HPR-resistant cells. The
pattern of RAR expression and the expression of markers
associated with differentiation and tumour progression was also
examined and compared with that of sensitive cells. 
MATERIALS AND METHODS 
Cell culture, conditions and drugs 
HPR resistant cells were obtained by culturing parental A2780
cells with increasing concentrations of HPR. Cells were initially
cultured with 1 mM HPR and drug concentration was increased by
1 mM every 5 passages up to 5 mM. Then cells were maintained
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continuously in 5 mM HPR (A2780/HPR). The cells were grown
in monolayer in RPMI 1640 medium containing 10% fetal bovine
serum (FBS) in 5% CO2 at 37˚C. HPR, all-trans-retinoic acid
(RA), 13-cis-retinoic acid (13-cis-RA), N-(4-methoxyphenyl)retin-
amide (MPR), and 6-[3-adamantyl-4-hydroxyphenyl]-2-naphtha-
lene carboxylic acid (CD437) were dissolved at 30 mM in
DMSO prior to further dilution in culture medium. HPR and MPR
were kindly provided by RW Johnson Pharmaceutical Research
Institute (Spring House, PA, USA) and CD437 by CIRD/Galderma
(Sophia Antipolis, France). RA and 13-cis-RA were purchased
from Sigma (Milan, Italy). 
Cell diameters were measured by Coulter Counter Multisizer II
(Coulter, Luton, UK). 
Growth inhibition assay 
Growth inhibition assays were performed as previously described
(Supino et al, 1996). Briefly, cells were treated with different
concentrations of the drugs, 24 h after seeding, for 3 days. Cell
number was determined by counting trypsinized cells using a ZBI
electronic particle Counter (Coulter). All data are presented as
means of duplicate cultures obtained from at least 2 independent
experiments. 
Colony formation assay 
For determination of the clonogenic ability, 35-mm diameter
dishes were first layered with 0.5% agarose/2´ RPMI supple-
mented with 10% FBS. A top layer containing 5000 cells plate–1
suspended in 0.3% agarose/2´ RPMI supplemented with 10%
FBS was then added. For the assay HPR was removed from the
medium of the resistant cells. Dishes were maintained in 5% CO2
at 37˚C for 9 days. 
Northern analysis 
Total cellular RNA was isolated by the guanidium thiocyanate-
CsCl method. About 20 mg of total RNA was fractionated on a 1%
agarose gel, transferred to nylon filters and probed with 32P-
labelled hRARa, hRARb or hRARg cDNAs, as previously
reported (Supino et al, 1996). A similarly labelled human glycer-
aldehyde-3-phosphate dehydrogenase (GAPDH) cDNA probe was
used for assessment of RNA loading. 
Immunoblot analysis 
Cells were lysed in Laemmli sample buffer containing 5% b-
mercaptoethanol and boiled for 3 minutes. Aliquots containing 80 mg
of total cell proteins were fractionated on 12% SDS-PAGE and
transferred to nitrocellulose membranes (Amersham Life Science
Inc, Arlington Heights, IL, USA). Membranes were blocked in 5%
non-fat milk in Tris-buffered saline (TBS) for 1 h at room temper-
ature and then incubated overnight at 4˚C with rabbit polyclonal
antibodies raised against hRARb (Santa Cruz Biotechnology Inc,
Santa Cruz, CA, USA). After washing in TBS containing 0.1%
tween 20, the filters were incubated with peroxidase antirab-
bit immunoglobulin G and specific complexes were revealed by
chemiluminescence according to the ECL (Enhanced Chemilumi-
nescence) Western blotting detection system Kit (Amersham). 
Flow cytometric analysis 
Cells, either living or after cell fixation/permeabilization with 70%
cold ethanol for 20 min, were incubated with primary antibody (10
mg ml–1 in phosphate-buffered saline containing 0.03% bovine
serum albumin) for 30 min on ice. Primary monoclonal antibodies
purified from hybridomas maintained in the laboratory (Dolo et al,
1997) were: MAR4 against b1 integrin, W6/32 against HLA class
I (ATCC, Rockville, MD), MluC5, against the 67 kDa laminin
receptor (LNR), Mint5 against the HER-1/EGFR 
(HER-1), MGR6, against HER-2/ErbB-2 (HER-2), Mov18,
directed against the folate receptor a (aFR). Commercial mono-
clonal antibodies or rabbit polyclonal antibodies used were: 
anti-caveolin 1, purchased from Santa Cruz (Santa Cruz
Biotechnologies) and anti-cytokeratins 8/18 purchased from Novo
Castra (Novo Castra Laboratories Ltd, Newcastle-upon-Tyne,
UK). After washing with PBS, cells were incubated with fluores-
cein-labelled goat anti-mouse IgG (Kirkegaard and Perry
Laboratories Inc, Gaithersburg, MD, USA) for 30 min on ice.
Cell-associated fluorescence was analysed using a flow cytometer
(FACScan, Becton Dickinson, Collaborative Research, Bedford,
MA, USA). Expression levels for each marker were evaluated as
fluorescence intensity in the presence of the relevant antibody and
compared to the background-staining value obtained from cells
incubated with fluoresceinated antibody only. 
Tumorigenicity assay 
Cultured cells were harvested by trypsinization, washed and resus-
pended in 0.9% NaCl. Cell suspensions were injected s.c. as 2.5 ´
106 cells and i.p. as 15 ´ 106 cells which correspond to the onco-
genic doses 100% s.c. and i.p. respectively of A2780 cells. Cells
were injected in 0.2 ml volume in 7–9-week-old CD-1 nu/nu
female mice (Charles River, Calco, Italy). Mice were monitored
for tumour onset and tumour growth twice a week. In s.c.-injected
mice, tumour diameters were measured by a caliper, and tumour
weights were estimated according to the formula: weight (g) =
[width (cm)]2 ´ length (cm)/2. 2 experiments were performed, and
the growth of the resistant cells was compared with that of the
parental cells. Statistical analysis was performed by Fisher’s exact
test for evaluation of tumour takes (i.e., number of tumours de-
veloped out of number of tumour injections) and the 2-tailed
Student’s t-test for the evaluation of tumour growth (i.e., number
of days to reach a tumour weight of 0.1 and 1 g). 
Animal studies were reviewed and approved by the ethics
Committee for Animal Experimentation of the Istituto Nazionale
Tumori (Milan, Italy) and are in accordance with the guidelines of
the UK Coordinating Committee on Cancer Research (UKCCCR,
1988). 
Measurement of intracellular reactive oxygen species 
The intracellular generation of reactive oxygen species was
measured by use of the oxidation-sensitive fluorescent dye
2¢, 7¢-dichlorofluorescein diacetate (DCF-DA) (Molecular Probes,
Eugene, OR, USA). Cells were seeded at 1 ´ 105 cells well–1 in 48
wells plates. 24 hours after seeding, cells were washed twice with
Hank’s balanced salt solution (Gibco BRL, Gaithersburg, MD,
USA) and 250 ml Hank’s balanced salt solution were added. HPR
was added at a final concentration of 10 mM and DCF-DA at a
final concentration of 10 mg ml–1. After 15 minutes incubation at1530 V Appierto et al 
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37˚C, the fluorescence was measured at 15 minutes intervals for up
to 190 minutes at 530 nm after excitation at 480 nm in a cytofluo-
rometer 2350 Fluorescence Measurement System (Millipore
Bedford, MA, USA). 
HPR uptake and metabolism 
The intracellular content of HPR was evaluated by HPLC as previ-
ously described (Formelli et al, 1993; Supino et al, 1996). Cells
were seeded and incubated for 24 h. They were then treated with 
1 mM HPR and 1, 4, 6, 8, 24, 48 and 72 h after HPR addition,
medium was removed and cells were scraped and washed 3 times
in 0.9% NaCl. The pellets were then frozen and kept for up to 1
week at –20˚C until drug assay. After thawing, cell pellets were
resuspended in 1 ml of distilled water containing 125 mg ml–1 of
butylated hydroxytoluene (BHT) (Sigma, St Louis, MO, USA) as
anti-oxidant and sonicated. 200 mL of each cell sample were added
to 400 ml CH3CN containing 125 mg ml–1 BHT, vortex mixed and
centrifuged to pellet the precipitated proteins. The recovered
supernatants were analysed on a liquid chromatograph (Perkin
Elmer, Norwall, CT, USA) fitted with a C18 (5 mm) reverse-phase
column (150 ´ 4.6 mm) and a C18 precolumn (Perkin Elmer,
Milan, Italy). The mobile phase consisted of CH3CN:H2O:
CH3COOH (75:23:2, vol/vol/vol) delivered at a flow rate of 2 ml
min–1. Detection was performed with a Perkin Elmer LC95
absorbance detector at 340 nm. N-(4-etoxyphenyl)-retinamide
(EPR) was used as internal standard by adding it to the CH3CN
used to precipitate the proteins. The reference standards HPR,
MPR and the internal standard EPR were supplied by the RW
Johnson Pharmaceutical Research Institute. RA and retinol, used
as reference standard were obtained from Sigma. All the proce-
dures were performed with the samples protected from light. The
protein content of each sample was evaluated in parallel by the
BCA Protein Assay Reagent (Pierce, Rockford, IL, USA). 
RESULTS 
A2780/HPR cells: morphological and growth
characteristics and sensitivity to other retinoids 
HPR-resistant cells were obtained after 20 passages of A2780 cells
by culturing them with increasing concentration of HPR up to
5 mM. These cells were subsequently maintained in the presence
of the highest employed concentration. HPR resistance was not
associated with changes in the proliferation rate (doubling time =
19–20 h). The effect of HPR on the proliferation of parental and
HPR-resistant cells was evaluated after 3 days of exposure to the
drug (Figure 1). In A2780 cells 50% growth inhibition was
achieved with approximately 1 mM HPR. The resistant index (RI)
of resistant cells was slightly higher than 10. To assess the stability
of HPR resistance, A2780/HPR cells were split and subcultured
for 5 passages without HPR (A2780/HPR/rev) (Figure 1). A2780/
HPR/rev cells showed a lower degree of resistance (RI = 5) than
A2780/HPR cells. To investigate whether the resistance to HPR
was associated to resistance to other retinoids, the effects of RA,
13cis-RA, MPR, and CD437 were evaluated on A2780 and
A2780/HPR cells (Figure 1). No differences in sensitivity to
CD437 were observed between A2780 and A2780/HPR cells. In
both cell lines CD437 caused a strong dose-dependent growth
inhibition: 50% growth inhibition was achieved with 0.5 mM. RA
and MPR were ineffective in both cell lines at doses up to 10 mM.
Relative to the parental counterpart, A2780/HPR cells showed
limited cross-resistance to 13cis-RA. The retinoid caused a slight
dose-independent growth inhibition of A2780 cells whereas it was
ineffective in A2780/HPR cells. 
Morphological differences between parental and resistant cells
could be observed (data not shown). A2780 parental cells were
heterogeneous in shape. In contrast resistant cells were round, and
reduced in size. The average cell diameter, evaluated in the
stationary phase, was 12 mm for resistant cells and 15 mm for
parental cells. Additionally, resistant cells formed foci-like aggre-
gates. 
The clonogenic assay, performed in agar, showed a 3-fold
reduction in colony-forming ability of A2780/HPR cells compared
with parental cells (plating efficiency 3.52 ± 0.063% vs 1.05 ±
0.4%) when a cut-point of 100 mm for colony diameter was fixed.
The reduction in colony-formation ability of resistant cells was
associated with a 3-fold reduction in mean colony diameter (584 ±
24 mm vs 146 ± 3.46 mm) (data not shown). The observed reduc-
tion in colony formation ability of A2780/HPR cells was not due
to possible exclusion of some colonies because of their smaller
size. In fact a reduction was also observed by counting colonies of
more than 50 cells (plating efficiency 5.15 ± 0.052% vs 2.11 ±
0.21%). 
140
120
100
80
60
40
20
0
0.1 1 10
HPR
140
120
100
80
60
40
20
0
0.1 1 10
CD437
140
120
100
80
60
40
20
0
0.1 1 10
RA
140
120
100
80
60
40
20
0
0.1 1 10
MPR
140
120
100
80
60
40
20
0
0.1 1 10
13cisRA
C
e
l
l
 
n
u
m
b
e
r
 
(
%
 
o
f
 
c
o
n
t
r
o
l
)
mM
Figure 1 Antiproliferative effect of HPR, CD437, RA, MPR, and 13-cis-RA
on A2780 (n) and A2780/HPR (∆ ) cells. The effect of HPR was also
evaluated on A2780/HPR/rev (s) cells. Cells were treated 24 h after seeding
and surviving cell number was evaluated 3 days later. Data are the means of
3 independent experiments Decreased drug accumulation in HPR-resistant cells 1531
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RARs expression in A2780/HPR cells 
To understand whether nuclear RARs are involved in the develop-
ment of HPR resistance, RAR a, b and g mRNA levels were eval-
uated in parental and resistant cells. A2780/HPR cells showed
RARa and RARg mRNAs levels similar to those of A2780 cells
(data not shown). However RARb expression in resistant cells was
markedly increased at the mRNA and protein level (Figure 2A and
2B, respectively). In A2780/HPR/rev cells, obtained by culturing
resistant cells without the drug for 5 passages (Figure 2B), RARb
protein expression was decreased compared to A2780/HPR cells,
but the levels were still higher than those of the parental line. 
Effect of HPR resistance on expression of markers of
adhesion, differentiation and tumour progression 
FACs analysis (Table 1) revealed no significant difference
between A2780 and A2780/HPR cells in expression of HLA class
I molecules on the cell surface and vimentin within the cells.
Moreover caveolin 1 expression, which characterizes the internal
leaflet of the plasma membrane of endothelia, fibroblasts and
several differentiated epithelia, was not modified upon acquisition
of HPR resistance. In contrast cytokeratin 8/18 was reduced and
the level of expression of b1 integrin, which was already low,
dropped below the limit of detectability in resistant cells. Among
the analysed tumour progression markers, the negative expression
of HER-1 and a-FR, a marker of non-mucinous ovarian carci-
noma, in parental cells was unaffected. Conversely LNR was
reduced and the level of expression of HER-2 was below the limit
of detectability in the resistant line A278/HPR. 
Tumorigenicity of A2780/HPR cells 
To study the possible role of the increased expression of RARb,
the reduced colony-forming ability and the reduced expression of
markers associated with aggressiveness in the in vivo tumori-
genicity of cells made resistant to HPR, A2780/HPR cells were
injected s.c. or i.p. into nude mice and their growth was compared
with that of the parental line (Table 2). The number of takes and
the growth pattern of A2780/HPR cells did not differ from that of
the parent line after s.c. or i.p. injection. 
Generation of reactive oxygen species in A2780 and
A2780/HPR cells 
The effect of HPR on generation of reactive oxygen species was
measured in A2780 and A2780/HPR cells. Cells were treated with
a high HPR concentration (10 mM) in order to better detect reac-
tive oxygen species generation at short times after drug exposure.
No difference in the rate or levels (250% increase compared
to controls at 180 min) of reactive oxygen species was found
between sensitive and resistant cells (data not shown). 
HPR uptake and metabolism in A2780 and A2780/HPR
cells 
The intracellular drug content of A2780 and A2780/HPR cells was
evaluated by HPLC analysis. Cells were exposed for 72 h to 1 mM
HPR, a concentration which corresponds to the IC50 in A2780 cells
and which is inactive in A2780/HPR cells. The representative
chromatograms of cells after 72 h in the presence of HPR, are
presented in Figure 3A. The initial peak (a), coeluting with the
front of the solvent, and peak b, corresponding to BHT, used as
antioxidant, were also found in cells not exposed to HPR. In cell
extracts from A2780 cells, only 2 peaks were found: peak 2 (reten-
tion time (R.T.) = 3.3 min), corresponding to an unidentified
metabolite, and peak 3 (R.T. = 3.7 min), corresponding to HPR. In
A2780/HPR cells besides peaks 2 and 3, an extra peak with a R.T.
of 1.3 min was found. No peak corresponding to RA (R.T. =
4.2 min), to retinol (R.T. = 4.6 min) or to MPR (R.T. = 6.3 min)
was detected in A2780 and A2780/HPR cells. The levels of HPR
and of the unidentified metabolites, as ng mg–1 proteins, in sensi-
tive and in resistant cells are reported in Figure 3B. If the levels are
expressed as ng cell–1 number, the results are comparable because
sensitive and resistant cells had similar protein levels. The time
course study showed that A2780 and A2780/HPR cells both
reached peaks of intracellular HPR concentrations at 4 h. The peak
levels of HPR in A2780/HPR cells were 2 times lower than those
of the parent line (1280 vs 2496 ng mg–1 protein). Nonetheless,
drug levels at later observation times (48–72 h) were similar and
the areas under the curves (AUC0–72 h) were 45.9 and 63.1 mg h–1
mg–1 protein for resistant and sensitive cells, respectively. The
unidentified metabolites (peak 2 in A2780 and peaks 1 and 2 in
A2780/HPR cells) were detected starting at 24 h. The concentra-
tions of each metabolite, evaluated as HPR equivalents, repre-
sented, at 72 h, approximately 20% of the total retinoid content. 
DISCUSSION 
In the study we have analysed the mechanisms and the molecular
characteristics associated with the induction of HPR resistance in a
human ovarian carcinoma cell line. We hypothesized that HPR
resistance might occur, as with cytotoxic drugs, due to continuous
drug exposure. We have shown that when A2780 ovarian tumour
cells, which are very sensitive to the growth inhibitory effect
of HPR, were exposed continuously to the retinoid HPR, they
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Figure 2 (A) Northern analysis for RARb expression in A2780 and
A2780/HPR cells. As a control for loading, the filters were stripped and
rehybridized with GAPDH. (B) Western analysis for RARb expression in
A2780, A2780/HPR and A2780/HPR/rev cells. As a control for loading the
blots were incubated with b-actin antibody became resistant. The growth of A2780 cells was 50% inhibited
by 1 mM HPR, a pharmacologically achievable concentration
(Formelli et al, 1993), whereas concentrations 10 times higher,
probably associated with severe side effects, were required to
obtain the same effects in A2780/HPR cells. The resistance to
HPR was reversible, thus indicating that the presence of the drug is
necessary to maintain the resistance phenotype. Resistance to HPR
was not associated to differences in sensitivity to the synthetic
retinoid CD437. Consistent with this finding, it was recently
reported that an acute promyelocytic leukaemia cell line, made
resistant to CD437, did not display any cross-resistance to HPR
(Ponzanelli et al, 2000). Such results indicate that the 2 retinoids
exert their growth inhibitory effects through different mechanisms
of action and moreover they suggest that combination of the 2
retinoids might result in improved efficacy. RA and MPR were
ineffective against A2780 and A2780/HPR cells whereas 13-
cisRA showed a slight level of cross-resistance with 4-HPR on
A2780/HPR cells. The significance of this effect is not known. 
The nuclear retinoid pathway (Fanjul et al, 1996) and oxidative
stress (Oridate et al, 1997) have been found to be operative in
mediating HPR growth-inhibitory effects. We previously showed
that RARs’ expression is involved in the apoptotic effect of HPR
in parental A2780 cells (Pergolizzi et al, 1999). In the cells, eleva-
tion of RARb expression levels by stable transfection resulted in
increased sensitivity to some HPR concentrations. In contrast, in
this study, the observed RARb elevation was associated with HPR
resistance. We also previously demonstrated that in A2780 cells, a
short (6 h) HPR treatment caused an increase in RARb mRNA
levels (Pergolizzi et al, 1999). Therefore, the marked increase in
RARb expression found in HPR-resistant cells, compared with
parental cells, seems to be the result of continuous induction, due
to the presence of HPR in the medium, rather than an intrinsic
characteristic of resistant cells. The hypothesis is compatible with
the fact that when HPR was eliminated from the medium for 5
passages, the levels of RARb expression decreased. A recent
report showed that HPR may exert 2 separate effects in F9 terato-
carcinoma cells: early cell killing at high doses (10 mM) and late
differentiation at low doses (1 mM) (Clifford et al, 1999). Likewise
in our system, cells surviving HPR continuous treatment showed a
more differentiated morphology than parental cells. The expres-
sion of some of the investigated markers was compatible with
enhanced differentiation. Parental A2780 cells coexpressed
vimentin, which is a component of stromal matrix origin, and
cytokeratin 8/18 which is characteristic of simple epithelia. The
observed reduction of cytokeratin 8/18 might be a consequence of
the induction of a more differentiated phenotype. The expression
of HER-2, a transmembrane glycoprotein receptor which is over-
expressed in approximately 30% of ovarian carcinoma, and which
1532 V Appierto et al 
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Table 2 Tumorigenicity of parental ovarian carcinoma cell line A2780 and HPR-resistant cell line A2780/HPRa
Cells  s.c. injection  i.p. injection 
No. of tumours/ Tumour latency Tumour growth No. of tumours/  Tumour latency 
No. of injections (days at 0.1 g) (days at 1 g) no. of injections (days at tumour onset)
A2780  8/9  10.9 ± 3.9  16.7 ± 7.2  9/10  31.2 ± 7.6 
A2780/HPR  8/8  7.7 ± 2.2  16.2 ± 3.6  8/10  30.4 ± 5.1 
aMice were injected s.c. with 2.5 ´ 106 cells and i.p. with 15 ´ 106 cells which correspond to the oncogenic doses 100% of A2780 cells
after i.p. and s.c. route, respectively. Mice were checked for tumour latency and growth (mean ± SD) as described in Material and
Methods.
Table 1 Expression of markers on parental ovarian carcinoma cell line A2780 and HPR resistant
cell line A2780/HPRa
Marker expression 
A2780 A2780/HPR  Marker
% MFI  %  MFI  Variation 
HLA class I  36.3  10.42  39.4  10.96  Û(+) 
Caveolin 1*  99.7  182.60  99.0  164.29  Û(+) 
Vimentin* 95.4  210.58  97.6  195.86  Û(+) 
Cytokeratin 8/18*  55.9  33.39  33.2  22.04  ß(+) 
b1 integrin  20.9  19.68  10.0  6.79  ß(+ to –) 
HER 1  7.5  8.68  6.9  9.13  Û(–) 
aFR 9  18.83  9  22.02  Û(–) 
LNR 33  45.03  24.5  23.13  ß(+) 
HER 2  40.1  18.53  19.6  6.68  ßß (+ to –) 
aBy FACS analysis on live or permeabilized cell suspensions: the reported data refer to a single
experiment. Similar data were obtained in 2–4 repeated experiments. % = % of positive cells. MFI
= mean fluorescence intensity of positive cells. Cut off level of positivity (+): more than 10% with a
MFI > 10%. Negative staining (–) i.e. no specific fluorescence over the background level in
presence of the FITC fluorescein-labelled secondary antibody alone. Û = reduction of total
fluorescence (% of positive cells ´ MFI) < 20%; ß = reduction 20–80%; ßß = reduction > 80%. 
*Cells were permeabilized with 70% EtOH on ice for 20 minutes. Decreased drug accumulation in HPR-resistant cells 1533
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correlates with poor survival (Berchuck et al, 1990) dropped
below the level of detectability. Laminin receptor expression,
which is correlated with ovarian tumour progression (Van der
Brule et al, 1996) was decreased. Finally b1 integrin, which has a
relevant role in inflammation, cell adhesion and migration and
which is activated during tumour progression and invasion, disap-
peared, thus suggesting a reduced metastatic phenotype of resis-
tant cells. The disappearance of b1 integrin from the cell surface
and the reduced levels of LNR are also consistent with the change
in morphology of A2780 HPR resistant cells. Reduction in HER-2
(Pellegrini et al, 1995) and b1 integrin (Rozzo et al, 1997) expres-
sion have also been found in other tumour cells after a single HPR
treatment. The continuous expression of RARb, a putative tumour
suppressor (Houle et al, 1993) and the reduced expression of
tumour aggressiveness markers may be the reason for the lower
colony-forming potential of the HPR-resistant cells. However, the
reduced clonogenic ability of resistant cells was not sufficient to
result in reduced in vivo tumorigenicity.
Our results indicate that HPR-resistance is not related to
different rates of generation of intracellular reactive oxygen
species and that reactive oxygen species are not important media-
tors of HPR-induced growth inhibitory effects in A2780 cell.
As it often occurs with cytotoxic drugs, resistance induced by
continuous exposure to HPR was associated with decreased
intracellular drug levels. The peak levels of HPR were 2 times
lower in resistant cells and the AUC0–72 h was reduced by 30%. The
mechanism responsible of the cellular HPR uptake is not known.
The reduced peak levels might be due to impairment in drug
uptake or they might reflect the reduced volume of resistant cells.
At variance with peak levels, the intracellular HPR levels at late
observation times (48–72 h) did not differ in the 2 cell types, thus
indicating similar late drug release. Interestingly, in NB4
leukaemia cells, made resistant to the synthetic retinoid CD437,
resistance was not associated to decreased drug uptake (Ponzanelli
et al, 2000).
Besides showing reduced peak levels, resistant cells showed a
different pattern of HPR metabolism. A polar metabolite, not
detected in sensitive cells, was found in cell extracts from resistant
cells. Perhaps cells sensitive to HPR activate, after continuous
exposure to the drug, new catabolic pathways in order to protect
themselves from the drug growth inhibitory effects. It is inter-
esting to note that in tumour cells, sensitive and naturally resistant
to RA, sensisitivity to the growth inhibitory effect of the retinoid
was correlated with the ability to metabolize it to polar metabolites
(Braakhuis et al, 1997; Van der Leede et al, 1997). The nature and
the role of the polar metabolite found in resistant cells are
currently being elucidated in our laboratory. Another metabolite
slightly more polar than HPR was found in sensitive and resistant
cells. This compound is not an impurity in HPR because it was not
found in the administered HPR solution and its concentrations
increased with time. Neither RA nor MPR, a major HPR metabo-
lite, which reaches in human plasma concentrations similar to
those of the parent drug (Formelli et al, 1993), was detected in
either cell line, thus indicating that such metabolic pathways do
not occur in the cells. 
Up to now only few in vitro models had been developed to study
mechanisms and characteristics of acquired retinoid resistance.
Here we have described the first in vitro model of acquisition of
HPR resistance. In summary, we have presented evidence that
continuous exposure of tumour cells to HPR results in induction of
HPR resistance. HPR resistance is associated with decreased peak
drug levels and with changes in marker expression that may be
interpreted as indicative of increased cell differentiation. We have
also shown that HPR metabolism in A2780/HPR cells is different
than in parental cells. Should this metabolic pathway occur in all
HPR resistant cells, it might represent a marker for HPR-induced
resistance. 
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